For the second year in a row, Quintiles has been named the industry leader that best differentiates itself on service quality for phase II/III research in Industry Standard Research’s (ISR) 2014 CRO Quality Benchmarking phase II/III Service Providers Report. According to the 148 pharmaceutical and biotechnology decision makers surveyed by ISR in this year’s report, Quintiles is the preferred provider for phase II/III research among small, mid-size and large biopharmaceutical companies.
“At Quintiles, we are focused on leading our customers through an increasingly complex and ever-changing drug development landscape,” said Paula Brown Stafford, President of Clinical Development, Quintiles. “We are delighted once again to be recognised as the industry leader in phase II/III research. This distinction is a result of the work of our tremendous teams around the world and underscores our unique ability to connect insights, expertise and capabilities across our organisation to improve the probability of success for our customers.”
In the survey, Quintiles outperformed all other large CROs across all customer loyalty- related measures, which are defined by overall satisfaction, willingness to recommend, and likelihood to use Quintiles again. Quintiles also rated higher than all large CROs in a number of selection criteria, including: Breadth of services; Therapeutic expertise; Commercial market, local market and regulatory knowledge; Data quality; Technology for real-time data access; Speed of site start-up; Patient recruitment strategy.
Survey respondents were decision-makers with large, mid-size and small biopharma companies who were involved in outsourced clinical study activities and phase II/III clinical trials within the past 18 months.
EP News Bureau – Mumbai